ArticleFrontiers in surgery2025
Clinical study of vacuum-assisted excision of deep breast nodules via the retromammary space.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the therapeutic efficacy of retromammary-space vacuum-assisted excision (VAE) and non-retromammary VAE for deep breast nodules ≤3 cm in maximum diameter, providing a clinical basis for selecting the optimal surgical approach. Methods: A retrospective analysis was conducted on the clinical data of 162 patients who underwent minimally invasive surgery for deep breast nodules at Weifang Maternal and Child Health Hospital between May 2022 and November 2024. Among them, 81 patients received retromammary-space VAE, while another 81 underwent non-retromammary VAE. Based on nodule size, the retromammary-space VAE group was further divided into two subgroups: the 0-2 cm group ( Results: Compared with non-retromammary VAE, retromammary-space VAE demonstrated statistically significant advantages ( Conclusion: Retromammary-space VAE for deep benign breast nodules can effectively reduce intraoperative bleeding, shorten operative time, and lower the incidence of complications such as pectoralis muscle injury and hematoma. This technique allows precise puncture positioning beneath the nodule, minimizes the number of punctures, and maintains this advantage regardless of nodule size, demonstrating promising clinical applicability and potential for wider adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.